RECEIVED #17 DOK

TECH CENTER 1600/2900 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:

Sim, Gek-Kee Yang, Shumin Dreitz, Matthew J. Wonderling, Ramani S.

Serial No.: 09/451,527

Filed: December 1, 1999

Atty. File No.: IM-2-C2

For: "CANINE AND FELINE

IMMUNOREGULATORY PROTEINS, NUCLEIC ACID MOLECULES, AND

USES THEREOF"

Commissioner for Patents Washington, DC 20231

Dear Sir:

In response to the Restriction Requirement dated March 13, 2001, Applicants hereby elect Group 20, without traverse. Applicants respectfully submit that Group 20 should include Claim 21 as well as cited Claims 18, 19, 23, 24, 26-28.

Applicants reserve the right to traverse restrictions between the remaining Groups in subsequent divisional applications. Applicants also reserve the right to file a divisional application relating to these claims without the necessity of filing a terminal disclaimer.

In any event, if the elected claims of Group 20 are allowable, Applicants reserve their right to amend the claims of Group 53, which Applicants submit should include Claim 32 rather than Claim 30, to be commensurate in scope with the product claims of Group 20, and to request that the claims of Group 53 that depend from or otherwise include all the limitations of the

Group Art-Unit: 1633

APR 1 9 2001

Examiner: Kaushal, S.

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

CERTIFICATE OF MAILING

Y OF APRIL 2001. HESKA CORPORATJON

v XI

allowable product be rejoined and examined for patentability. *In re Brouwer*, 37 USPQ2d 1663 (Fed. Cir. 1996); *In re Ochiai*, 37 USPQ2d 1127 (Fed. Cir. 1995).

Should any fees be due with the filing of this paper, please charge deposit account No. 081930.

Respectfully submitted,

Dated: April 13, 2001

Carol Talkington Verser, Ph.D.

Registration No. 37,459

Heska Corporation

1613 Prospect Parkway Fort Collins, Colorado 80525

Telephone: (970) 493-7272 Facsimile: (970) 491-9976